Neodynamics

0,075 SEK +6,28 %

HC Andersen Capital modtager betaling fra Neodynamics for en Digital IR/Corporate Visibility abonnementsaftale. Læs mere her.

6 investorer følger denne virksomhed

www.neodynamics.com/sv-se/investerare

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.

Omsætning

140 t

EBIT %

-52.307,14 %

P/E

Udbytteafkast, %

Kursmål

Anbefaling

Opdateret

First North Stockholm

NEOD

Daglig lav / høj pris

0,07 / 0,075 SEK

Markedsværdi

52,07 mio. SEK

Aktieomsætning

18,05 t SEK

Volumen

247 t

Seneste analyser

NeoDynamics - Equity Research Report - Company sponsored

22.12.2022

Analyst

Claus Thestrup

CEO, Sweden

Seneste videoer

Life Science seminar

31.08.2023

NeoDynamics – Presentation of Q2 2023

01.08.2023

NeoDynamics - Presentation of Q1 interim report 2023

12.05.2023

Finanskalender

Delårsrapport

17.11.2023

Årsrapport

16.02.2024

Major Owners
Source: Millistream Market Data AB

Owner	Capital	Votes
Gryningskust Holding AB	14,0 %	14,0 %
Huasheng Fang	11,3 %	11,3 %

Premium

Not activated

This content is for our Premium customers only.

Forum opdateringer

Hold dig opdateret med den seneste information fra Neodynamics

Læs hele tråden

Besøg forummet

NeoDynamics AB meddelte i går, at det indgår partnerskab med den globale distributions- og logistikgigant Uniphar Group for at sikre en succesfuld lancering af NeoNavia® i USA, dets innovative pulsbiopsisystem. NeoDynamics couldn’t be more pleased to be partnering with Uniphar, a proven global partner to pharma and MedTech companies. Leveraging Uniphar’s customer service, logistics management and digital technology will allow us to aggressively hit the US market. The relationship with Uniphar is a key corporate development as we put all the pieces in place for the successful US launch of NeoNavia, fortæller Anna Eriksrud CEO af NeoDynamics. Endnu et vigtig skridt for NeoDynamics i forbindelse med deres lancering af puls biopsi-systemet Neonavia på det amerikanske marked. Efter FDA godkendelsen i efteråret 2022 er der kommet fart på forberedelserne op til lanceringen. De har fået ledelse, partner til hjælp med lanceringen og nu også en distributionspartner på plads. Det totale marked for bryst biopsi vurderes til USD 830 mio. i 2025. Læs hele meddelelsen her.

Olivier A. de Goeij

for 7 måneder siden💙 1

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk: NeoDynamics AB (publ) er en svensk medicinsk teknologivirksomhed dedikeret til at fremme diagnosticering og behandling af brystkræft. Virksomhedens første produkt NeoNavia®, et nyt innovativt pulsbiopsisystem til ultralydsstyret vævsprøvetagning, er i øjeblikket ved at blive introduceret på markedet. Biopsisystemet er bygget på en patenteret pulsteknologi, baseret på forskning ved Karolinska Institutet i Sverige. NeoNavia er evalueret for brystkræftdiagnose på førende klinikker i Storbritannien, Tyskland og Sverige. Pulsbiopsisystemet er blevet brugt til vævsprøvetagning i bryst og aksillære lymfer hos over 500 patienter. English: NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing the diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in the breast and axilla in over 500 patients.

Olivier A. de Goeij

for 10 måneder siden

Viser Alle indholdstyper

NeoDynamics (“NeoDynamics” or the “Company”) provides a status update on the US market launch

Pressemeddelelse21.09.2023

Neodynamics

Last day of trading in paid subscribed unites (Sw. BTU) in NeoDynamics

Selskabsmeddelelse15.09.2023

Neodynamics

Life Science Seminar – Wrap up from our event last week – Thursday the 31st. of August.

Analytikerkommentar05.09.2023 af Henrik Ekman, Claus Thestrup

Bavarian Nordic BioPorto Gubra ExpreS2ion Biotech Holding

Life Science seminar

Videopræsentation31.08.2023 af Emilie Håkonsson Lohse

Bavarian Nordic Gubra ExpreS2ion Biotech Holding Ascelia Pharma

Redeye: NeoDynamics - Rights issue outcome and coverage resumed

Pressemeddelelse23.08.2023

Neodynamics

NeoDynamics announces outcome of rights issue

Selskabsmeddelelse21.08.2023

Neodynamics

Dagens Aktienyheder 16/08

Netcompany har her til morgen offentliggjort regnskab for 2. kvartal 2023. Skako offentliggjorde i går aftes foreløbige regnskabstal for 2. kvartal 2023. Gubra opjusterede forventningerne til 2023 i går. PEG Q2-tal selskabet kommer med en tab før skat på DKK 7,2 mio. AUDIENTES meddelte igår, at de har modtaget forudbetalinger på DKK 562t fra deres kinesiske partner. NeoDynamics - Last day to subscribe in rights issue.

Analytikerkommentar16.08.2023

Netcompany Group SKAKO Pharma Equity Group Audientes

NeoDynamics publishes supplement to prospectus

Selskabsmeddelelse11.08.2023

Neodynamics

NeoDynamics: Reaches important milestone in US

NeoDynamics reaches important milestone in US - First order received.

Analytikerkommentar10.08.2023 af Claus Thestrup

Neodynamics

Dagens Aktienyheder 10/08

DS NORDEN har her til morgen offentliggjort sit regnskab for 2. kvartal 2023. GreenMobility A/S aflægger i dag regnskab for første halvår af 2023. NeoDynamics reaches important milestone in US.

Analytikerkommentar10.08.2023

D/S Norden GreenMobility Neodynamics

NeoDynamics Receives First US Order from Top University Hospital

Selskabsmeddelelse09.08.2023

Neodynamics

Dagens Aktienyheder 02/08

BankNordik rapporterer efter planen sit regnskab for 2. kvartal 2023 i morgen – torsdag d. 3. august. BioPorto A/S har været ude med regnskab for Q2. NeoDynamics interview with management and rights issue starting today.

Analytikerkommentar02.08.2023

BankNordik BioPorto Neodynamics

The subscription period in NeoDynamics rights issue begins today

Selskabsmeddelelse02.08.2023

Neodynamics

Interview with management about events during Q2

Analytikerkommentar02.08.2023 af Claus Thestrup

Neodynamics

NeoDynamics – Presentation of Q2 2023

Meet and ask questions to CEO Anna Eriksrud and CFO Aaron Wong from NeoDynamics – Tuesday 1 August at 4:15 PM CEST CEO Anna Eriksrud will briefly update the investor community on the commercial development in US and Europe, and CFO Aaron Wong will run through the figures and the details regarding the rights issue.

Videopræsentation01.08.2023

Neodynamics

Meet CEO Anna Eriksrud and CFO Aaron Wong on todays event

Meet and ask questions to CEO Anna Eriksrud and CFO Aaron Wong on todays event

Analytikerkommentar01.08.2023 af Claus Thestrup

Neodynamics

Danske Bank Hydract Neodynamics

Bulletin from Extraordinary General Meeting in NeoDynamics AB (publ)

Selskabsmeddelelse27.07.2023

Neodynamics

Neodynamics

Seneste analyser

Analyst

Seneste videoer

Finanskalender

Major Owners
Source: Millistream Market Data AB

Premium

Forum opdateringer

NeoDynamics (“NeoDynamics” or the “Company”) provides a status update on the US market launch

Last day of trading in paid subscribed unites (Sw. BTU) in NeoDynamics

Life Science Seminar – Wrap up from our event last week – Thursday the 31st. of August.

Life Science seminar

Redeye: NeoDynamics - Rights issue outcome and coverage resumed

NeoDynamics announces outcome of rights issue

Dagens Aktienyheder 16/08

NeoDynamics publishes supplement to prospectus

NeoDynamics: Reaches important milestone in US

Dagens Aktienyheder 10/08

NeoDynamics Receives First US Order from Top University Hospital

Dagens Aktienyheder 02/08

The subscription period in NeoDynamics rights issue begins today

Interview with management about events during Q2

NeoDynamics – Presentation of Q2 2023

Meet CEO Anna Eriksrud and CFO Aaron Wong on todays event

NeoDynamics publishes prospectus in connection with the forthcoming rights issue

NeoDynamics Interim Report Jan-June 2023

Dagens Aktienyheder 28/07

Bulletin from Extraordinary General Meeting in NeoDynamics AB (publ)

Neodynamics

Seneste analyser

Analyst

Seneste videoer

Finanskalender

Major OwnersSource: Millistream Market Data AB

Premium

Forum opdateringer

NeoDynamics (“NeoDynamics” or the “Company”) provides a status update on the US market launch

Last day of trading in paid subscribed unites (Sw. BTU) in NeoDynamics

Life Science Seminar – Wrap up from our event last week – Thursday the 31st. of August.

Life Science seminar

Redeye: NeoDynamics - Rights issue outcome and coverage resumed

NeoDynamics announces outcome of rights issue

Dagens Aktienyheder 16/08

NeoDynamics publishes supplement to prospectus

NeoDynamics: Reaches important milestone in US

Dagens Aktienyheder 10/08

NeoDynamics Receives First US Order from Top University Hospital

Dagens Aktienyheder 02/08

The subscription period in NeoDynamics rights issue begins today

Interview with management about events during Q2

NeoDynamics – Presentation of Q2 2023

Meet CEO Anna Eriksrud and CFO Aaron Wong on todays event

NeoDynamics publishes prospectus in connection with the forthcoming rights issue

NeoDynamics Interim Report Jan-June 2023

Dagens Aktienyheder 28/07

Bulletin from Extraordinary General Meeting in NeoDynamics AB (publ)

Major Owners
Source: Millistream Market Data AB